Library Item - Page 31 of 792 Posts on Medivizor
Navigation Menu

Library Item Posts on Medivizor

Evaluating the effectiveness and safety of adding ixazomib to lenalidomide maintenance therapy in patients with newly diagnosed multiple myeloma after ASCT.

Evaluating the effectiveness and safety of adding ixazomib to lenalidomide maintenance therapy in patients with newly diagnosed multiple myeloma after ASCT.

Posted by on Apr 10, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding ixazomib (Ninlaro) to lenalidomide (Revlimid) maintenance therapy after autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (MM). The data showed that the addition of ixazomib to lenalidomide maintenance improved survival without cancer...

Read More

Evaluating the effectiveness and safety of low-intensity extracorporeal shock wave therapy for patients with chronic pelvic pain syndrome and erectile dysfunction.

Evaluating the effectiveness and safety of low-intensity extracorporeal shock wave therapy for patients with chronic pelvic pain syndrome and erectile dysfunction.

Posted by on Apr 10, 2022 in Erectile dysfunction | 0 comments

In a nutshell This study evaluated the effectiveness and safety of low-intensity extracorporeal shock wave therapy (LSWT) for patients with chronic pelvic pain syndrome (CPPS) and erectile dysfunction (ED). The data showed that LSWT was safe and effective in improving the symptoms of these patients. Some background CPPS is lower abdominal pain usually...

Read More

Evaluating the effectiveness and feasibility of patient-reported outcome-based symptom management versus usual care in patients after lung cancer surgery.

Evaluating the effectiveness and feasibility of patient-reported outcome-based symptom management versus usual care in patients after lung cancer surgery.

Posted by on Apr 10, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and feasibility of patient-reported outcome (PRO)-based symptom management versus usual care in patients after lung cancer surgery. The data showed that PRO-based symptom management after lung cancer surgery showed lower symptom burden and fewer complications than usual care for up to 4 weeks after...

Read More

Evaluating the effectiveness of anatomical versus non-anatomical resection in the surgery of lung metastases in patients with colorectal cancer.

Evaluating the effectiveness of anatomical versus non-anatomical resection in the surgery of lung metastases in patients with colorectal cancer.

Posted by on Apr 10, 2022 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness of anatomical resection (AR) versus non-anatomical resection (NAR) in the surgery of lung metastases for patients with colorectal cancer (CRC). The data showed AR significantly improved cancer-specific survival outcomes compared to NAR in the surgery of lung metastases for patients with CRC. Some...

Read More

Evaluating the long-term effectiveness of adding ribociclib to hormone therapy in younger patients with HR+/HER2- advanced breast cancer.

Evaluating the long-term effectiveness of adding ribociclib to hormone therapy in younger patients with HR+/HER2- advanced breast cancer.

Posted by on Apr 10, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the long-term effectiveness of adding ribociclib (Kisqali) to endocrine (hormone) therapy in pre-/perimenopausal patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding ribociclib to hormone therapy significantly improved survival outcomes than hormone...

Read More

Evaluating the effectiveness and safety of new antiandrogen SHR3680 in patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of new antiandrogen SHR3680 in patients with metastatic castration-resistant prostate cancer.

Posted by on Apr 10, 2022 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of a new hormonal therapy, SHR3680 (rezvilutamide), for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The study showed that SHR680 was well tolerated and had promising effectiveness in these patients. Some background Metastatic...

Read More

Does sipuleucel-T improve the survival of men with advanced prostate cancer treated with androgen receptor-targeting drugs?

Does sipuleucel-T improve the survival of men with advanced prostate cancer treated with androgen receptor-targeting drugs?

Posted by on Apr 10, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of adding sipuleucel-T (Provenge) androgen receptor-targeting agents (ARTAs) such as abiraterone acetate (AA; Zytiga) and enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer (mCRPC). The data showed that those receiving both sipuleucel-T and ARTAs were more...

Read More

Evaluating the combined daratumumab, lenalidomide and dexamethasone therapy for patients with multiple myeloma, based on frailty levels.

Evaluating the combined daratumumab, lenalidomide and dexamethasone therapy for patients with multiple myeloma, based on frailty levels.

Posted by on Apr 3, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study compared the effectiveness and safety of using daratumumab (Darzalex) with lenalidomide (Revlimid) and dexamethasone (Decadron)(D-Rd) to lenalidomide and dexamethasone (Rd) treatment in patients with newly diagnosed multiple myeloma (NDMM), based on frailty levels. The data showed that D-Rd was more effective than Rd at improving...

Read More

Can filgotinib affect patient-reported outcomes and health-related quality of life in patients with rheumatoid arthritis?

Can filgotinib affect patient-reported outcomes and health-related quality of life in patients with rheumatoid arthritis?

Posted by on Apr 3, 2022 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the effect of filgotinib (Jyseleca) on patient-reported outcomes (PROs) and health-related quality of life (HRQoL) in patients that had active rheumatoid arthritis (RA). The study showed that filgotinib improved PROs in these patients and can be a treatment option for patients with insufficient responses to...

Read More

Evaluating the effectiveness and safety of mosunetuzumab for patients with relapsed/refractory non-Hodgkin lymphoma.

Evaluating the effectiveness and safety of mosunetuzumab for patients with relapsed/refractory non-Hodgkin lymphoma.

Posted by on Apr 3, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of mosunetuzumab (RG7828) for the treatment of patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL). The data showed that mosunetuzumab resulted in long-lasting complete responses with manageable side effects for these patients. Some background NHL is cancer that...

Read More

Comparing the effectiveness and safety of immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone for triple-negative breast cancer.

Comparing the effectiveness and safety of immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone for triple-negative breast cancer.

Posted by on Apr 3, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of immune checkpoint inhibitors (ICI) plus chemotherapy versus chemotherapy alone for the treatment of patients with triple-negative breast cancer (TNBC). The data showed that ICI plus chemotherapy was more effective than chemotherapy alone and was associated with a higher rate of side...

Read More

Evaluating antibody response rates of patients with chronic lymphocytic leukemia to a third dose of mRNA COVID-19 vaccine

Evaluating antibody response rates of patients with chronic lymphocytic leukemia to a third dose of mRNA COVID-19 vaccine

Posted by on Mar 20, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the antibody response to a third mRNA COVID-19 vaccine of patients with chronic lymphocytic leukemia (CLL) who had failed to achieve an antibody response after the standard two-dose vaccination regimen.  This study concluded that approximately a quarter of patients responded to the third...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor